AI Terminal
Achiko AG
Report Publication Announcement • Jul 7, 2022
804_rns_2022-07-07_90452f32-1906-4239-bab9-4eb33dbca629.html
Report Publication Announcement
Open in ViewerOpens in native device viewer
News Details
Corporate | 7 July 2022 19:45
Achiko AG – Investor Briefing
Achiko AG / Key word(s): Miscellaneous
Achiko AG – Investor Briefing
07.07.2022 / 19:45
Achiko AG – Investor Briefing
Zurich, 7 J u ly 2022: Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”), would like to invite investors and shareholders to a moderated investor call. A powerpoint presentation will be available around the time of the call and published on the website.
Details are as follows:
Date: 8 July 2022
Time: 2.30pm CEST / 8.30am EDT
Format: Zoom Call
Presenter: Mr Steven Goh, CEO of Achiko AG
Meeting link: https://us02web.zoom.us/j/6191486127?pwd=VWJYa0VmWFV3OTBiL1RDd0o5NjR2dz09
Meeting ID: 619 148 6127
Passcode: 888
Find your local number: https://us02web.zoom.us/u/knHHcenwR
ABOUT ACHIKO A G
Achiko AG (SIX: ACHI.SW; OTCQB: ACHKF; ww w.achiko.com ) is developing disruptive diagnostic solutions that puts people first. The company’s lead product is a rapid, reliable Covid-19 test with a companion app offering a user-friendly digital health passport. The test and companion app were launched in Indonesia in mid-2021 and an application for CE Mark approval in Europe will be submitted in 2022.
Achiko creates and develops aptamer-based diagnostics through its biotechnology division, AptameX TM and companion health apps via its digital mobile health technology division, Teman Sehat TM . The AptameX DNA aptamer tests can be rapidly chemically synthesised, are cost-effective and have wide potential across multiple disease diagnostics. Leveraging AptameX and Teman Sehat, Achiko aims to deliver fast, accurate and affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications in the rapidly evolving healthcare diagnostics field.
Headquartered in Zurich, Achiko has offices in Jakarta, and staff around the world.
M edia contacts:
ACHIKO A G
Switzer l and & G lo b al
Marcus Balogh
Farner Consulting Ltd.
T: +41 44 266 67 67
Disclaimer
T his communi c a tio n expressl y or i m plicitly c o nta i ns certa i n f or w ard-look i ng s tatem e nts c o ncernin g A chik o A G an d it s business . Suc h stat e ment s in v olv e certai n k n o w n a n d un k no w n risks, uncer t ainties a n d othe r f actors, w hi c h coul d cause the actua l results, f i n ancial c o nditi o n, per f or m ance or achi e vement s o f A chik o A G to be material l y di ff erent f rom any f u t ure results, pe r f ormance or achiev e ments expressed or implie d by such f or w ard-l o oki n g statem e nts. A chiko A G is providing this com m uni c ati o n as o f this date and d oe s not u nder t ake to u p d ate a n y f or w ard- l ooki n g stat e ments contain e d herein as a result o f ne w in f ormat i on , f uture eve n ts or o ther w ise.
End of Media Release
| Language: | English |
| Company: | Achiko AG |
| Tessinerplatz 7 | |
| 8002 Zurich | |
| Switzerland | |
| E-mail: | [email protected] |
| Internet: | https://www.achiko.com/ |
| ISIN: | CH0522213468 |
| Valor: | 48788430 |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 1393507 |
| End of News | EQS News Service |